Skip to main content
SpringerLink
Log in

Vandetanib (ZACTIMA™; ZD6474): Preclinical and Clinical Development

  • Chapter
Tumor Angiogenesis

  • 1844 Accesses

Abstract

Vandetanib ( ZACTIMA™; ZD6474) is a once-daily, orally available agent with potential for use in a number of solid tumour types. Vandetanib targets key signalling pathways in cancer by inhibiting vascular endothelial growth factor receptor (VEGFR)-dependent tumour angiogenesis and epidermal growth factor receptor (EGFR)-dependent tumour cell growth and survival. Vandetanib also inhibits RET (rearranged during transfection) kinase activity, which is involved in the development of several human diseases, including medullary and papillary carcinomas of the thyroid. Preclinical studies of vandetanib have demonstrated potent inhibition of VEGFand EGF-stimulated human umbilical vein endothelial cell proliferation in vitro, as well as dose-dependent inhibition of tumour growth in a histologically diverse range of human tumour xenografts. Phase I studies showed vandetanib to be generally well tolerated at doses up to 300 mg per day, with a pharmacokinetic profile that supports once-daily oral administration. Common adverse events included rash, diarrhea and asymptomatic QTc prolongation, all of which were controlled by standard management. Phase II evaluation of vandetanib in patients with advanced, refractory NSCLC (non-small-cell lung cancer) has demonstrated improvements in progression-free survival, both as monotherapy (versus gefitinib) and in combination with docetaxel (versus docetaxel alone). These positive outcomes haveled to the initiation of phase III trials of vandetanib in a broad population of patients with advanced NSCLC. Clinical development is also ongoing in other tumour types, and encouraging evidence of antitumour activity has been reported in patients with metastatic hereditary medullary thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K (2004a) Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64:9101–9104

    Article  PubMed  CAS  Google Scholar 

  • Arao T, Yanagihara K, Takigahira M, Fukumoto F, Koizumi F, Nishio K (2004b) Antitumor effect of ZD6474 in a VEGF-producing primary gastric cancer model. Proc Am Assoc Cancer Res 45:1047

    Google Scholar 

  • Azzariti A, Porcelli L, Paradiso A (2003) In vitro activity of ZD6474 in combination with 7-ethyl-10-hydroxy-camptothecin (SN-38) on colon cancer cell line growth and survival. Clin Cancer Res 9:6148S

    Google Scholar 

  • Bradley DP, Tessier JT, Checkley DR, Kuribayashi H, Wedge SR (2004) The VEGF signaling inhibitors ZD6474 and AZD2171 compromise hemodynamic parameters in an SW620 human colon tumor model: an analysis using perfusion-permeability dynamic contrast-enhanced magnetic resonance imaging (pp-DCE-MRI). Proc Am Assoc Cancer Res 45:1051

    Google Scholar 

  • Bradshaw EL, Gustafson DL (2004) Inhibitory growth effect of ZD6474 alone and in combination with low-dose cytotoxic chemotherapy in mouse endothelial cells. Proc Am Assoc Cancer Res 45:882

    Google Scholar 

  • Briggs A, Molofsky D, Wang A, Engelman J, Beaudry P, Prox D, Tracy S, Ryan A, Folkman J, Janne P, Johnson BE, Heymach JV (2005) Sensitivity of NSCLC cell lines bearing wild-type and mutated EGFR to the VEGFR/EGFR inhibitor ZD6474. Proc Am Assoc Cancer Res 46: abstr 5833

    Google Scholar 

  • Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926–2935

    PubMed  CAS  Google Scholar 

  • Bruns CJ, Shrader M, Harbison MT, Portera C, Solorzano CC, Jauch KW, Hicklin DJ, Radinsky R, Ellis LM (2002) Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 102:101–108

    Article  PubMed  CAS  Google Scholar 

  • Bruns CJ, Kohl G, Guba M, Yezhelyev M, Wiegand U, Ryan A, Barge A, Geissler E, Jauch K-W (2003) Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Proc Am Assoc Cancer Res (2nd Ed) 44:604

    Google Scholar 

  • Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284–7290

    PubMed  CAS  Google Scholar 

  • Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M (2004) Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23:6056–6063

    Article  PubMed  CAS  Google Scholar 

  • Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR (2003) Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89:1889–1895

    Article  PubMed  CAS  Google Scholar 

  • Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, de Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459–1465

    PubMed  CAS  Google Scholar 

  • Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G (2003) Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546–1556

    PubMed  CAS  Google Scholar 

  • Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, de Vita F, de Placido S, Bianco AR, Tortora G (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784–793

    Article  PubMed  CAS  Google Scholar 

  • Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, de Placido S, Ciardiello F, Tortora G (2005) Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11:5639–5644

    Article  PubMed  CAS  Google Scholar 

  • Drevs J, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Esser N (2004) The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7:347–354

    Article  PubMed  CAS  Google Scholar 

  • Dvorak HF, Brown LF, Detmar M, Dvorak AM (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039

    PubMed  CAS  Google Scholar 

  • Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18

    PubMed  CAS  Google Scholar 

  • Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336–30343

    Article  PubMed  CAS  Google Scholar 

  • Gille J, Swerlick RA, Caughman SW (1997) Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 16:750–759

    Article  PubMed  CAS  Google Scholar 

  • Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121–133

    PubMed  CAS  Google Scholar 

  • Goodlad RA, Ryan A, Watson J, Wedge SR, Pyrah IT, Mandir N, Wilkinson RW (2004) Antitumor therapy with VEGF receptor tyrosine kinase inhibitor ZD6474 in a mouse model of intestinal cancer. EJC [Suppl] 2:51

    Google Scholar 

  • Gustafson DL, Merz AL, Zirrolli JA, Connaghan-Jones KD, Raben D (2004) Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts. EJC [Suppl] 2:45

    Google Scholar 

  • Hammett T, Oliver S, Ghahramani P, Kennedy S, Fisher I, Gilmore E, Duvauchelle T, Smith R (2005) The pharmacodynamic effect on cardiac repolarization of combination single dose ZD6474 and ondansetron in healthy subjects. Proc Am Soc Clin Oncol abstr 3197

    Google Scholar 

  • Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689–708

    Article  PubMed  CAS  Google Scholar 

  • Heffelfinger SC, Yan M, Gear RB, Schneider J, LaDow K, Warshawsky D (2004) Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation. Lab Invest 84:989–998

    Article  PubMed  CAS  Google Scholar 

  • Helfrich B, Troiani T, Raben D, Frederick B, Gustafson D, Merz A, Weed S, Bunn P (2004) Anticancer effects of ZD6474 in gefitinib (Iressa™) resistant lung cancer cell lines in vitro. EJC [Suppl] 2:51

    Google Scholar 

  • Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45:1300–1312

    Article  PubMed  CAS  Google Scholar 

  • Heymach JV, Dong R-P, Dimery I, Wheeler C, Fidias P, Lu C, Johnson B, Herbst R (2004) ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: results of the run-in phase of a two-part, randomized phase II study. Proc Am Soc Clin Oncol abstr 3051

    Google Scholar 

  • Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Špásová I, Hou J, Kennedy S, Herbst RS (2006) A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. Proc Am Soc Clin Oncol abstr 7016

    Google Scholar 

  • Hoang T, Huang SM, Armstrong EA, Harari PM (2004) Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474. Proc Am Assoc Cancer Res 45:955

    Google Scholar 

  • Holden SN, Eckhardt SG, Basser R, de Boer R, Rischin D, Green M, Rosenthal MA, Wheeler C, Barge A, Hurwitz HI (2005) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 16:1391–1397

    Article  PubMed  CAS  Google Scholar 

  • Horner A, Bishop NJ, Bord S, Beeton C, Kelsall AW, Coleman N, Compston JE (1999) Immunolocalisation of vascular endothelial growth factor (VEGF) in human neonatal growth plate cartilage. J Anat 194:519–524

    Article  PubMed  CAS  Google Scholar 

  • Ichihara M, Murakumo Y, Takahashi M (2004) RET and neu-roendocrine tumors. Cancer Lett 204:197–211

    Article  PubMed  CAS  Google Scholar 

  • Johnson BE, Ma P, West H, Kerr R, Prager D, Sandier A, Herbst RS, Stewart DJ, Dimery I, Heymach JV (2005) Preliminary Phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as first-line treatment in patients with NSCLC. Proc Am Soc Clin Oncol abstr 7102

    Google Scholar 

  • Jussila L, Alitalo K (2002) Vascular growth factors and lymphangiogenesis. Physiol Rev 82:673–700

    PubMed  CAS  Google Scholar 

  • Kovacs MJ, Reece DE, Marcellus D, Meyer RM, Mathews S, Dong RP, Eisenhauer E (2006) A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest New Drugs 24:529–535

    PubMed  CAS  Google Scholar 

  • Kurahara H, Takao S, Maemura K, Shinchi H, Natsugoe S, Aikou T (2004) Impact of vascular endothelial growth factor-C and-D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin Cancer Res 10:8413–8420

    Article  PubMed  CAS  Google Scholar 

  • Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A, de Waal R (2004) Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10:6222–6230

    Article  PubMed  CAS  Google Scholar 

  • Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306–1311

    PubMed  CAS  Google Scholar 

  • Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6:4064–4068

    PubMed  CAS  Google Scholar 

  • Matsumori Y, Goto H, Nakataki E, Kanematsu T, Yano S, Wedge S, Ryan A, Sone S (2003) ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase activity, inhibits growth of human non-small cell lung cancer metastases that are resistant to treatment with ZD1839. Proc Am Assoc Cancer Res (2nd Ed) 44:9

    Google Scholar 

  • McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ, Ellis LM (2004) ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 3:1041–1048

    PubMed  CAS  Google Scholar 

  • Miller KD, Hutchins G, Miller M, Badve S, Sledge GW (2003) ZD6474-mediated vascular changes in a breast cancer xenograft model illustrated by positron emission tomography. Clin Cancer Res 9:6139S

    Google Scholar 

  • Miller KD, Trigo JM, Stone A, Wheeler C, Barge A, Sledge GW, Baselga J (2004) A phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer (MBC). Breast Cancer Res Treat 88 [Suppl]: abstr 6060

    Google Scholar 

  • Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N (2003) A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor, ZD6474, in Japanese patients with solid tumors. Proc Am Soc Clin Oncol 194

    Google Scholar 

  • Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield KM, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O’Byrne KJ, Henry A, Cherryman GR, Leurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrokine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J Clin Oncol 21:3955–3964

    Article  PubMed  CAS  Google Scholar 

  • Natale RB, Bodkin D, Govindan R, Sleckman B, Rizvi N, Capo A, Germonpré P, Stockman P, Kennedy S, Ranson M (2006) ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. Proc Am Soc Clin Oncol abstr 7000

    Google Scholar 

  • Nicholson B, Guiding K, Conaway M, Wedge SR, Theodorescu D (2004) Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res 10:8728–8734

    Article  PubMed  CAS  Google Scholar 

  • Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS (2005) ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11:8145–8157

    Article  PubMed  CAS  Google Scholar 

  • Sandstrom M, Johansson M, Andersson U, Bergh A, Bergenheim AT, Henriksson R (2004) The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 91:1174–1180

    PubMed  CAS  Google Scholar 

  • Schietroma C, Cianfarani F, Lacal PM, Odorisio T, Orecchia A, Kanitakis J, D’Atri S, Failla CM, Zambruno G (2003) Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 98:789–797

    Article  PubMed  CAS  Google Scholar 

  • Shibuya K, Komaki R, Shintani T, Wu W, Itasaka S, Isobe T, Ryan A, Herbst RS, O’Reilly MS (2005) Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer. Proc Am Assoc Cancer Res 46: abstr 5828

    Google Scholar 

  • Shintani T, Lewis VO, Komaki R, Wu W, Ryan A, Herbst RS, O’Reilly MS (2005) ZD6474 inhibits human lung cancer bone metastases in a murine model by targeting both the tumor and its vasculature. Proc Am Assoc Cancer Res 46: abstr 5844

    Google Scholar 

  • Siemann D, Shi W (2004) The VEGFR2 tyrosine kinase inhibitor, ZD6474, enhances the antitumor effect of radiation. EJC [Suppl] 2:49

    Google Scholar 

  • Smith R, Kennedy S, Robertson J, Sandall D, Oliver R (2005) The effect of food on the intra-subject variability of the pharmacokinetics of ZD6474, a novel antiangiogenic agent, in healthy subjects. Proc Am Soc Clin Oncol abstr 3167

    Google Scholar 

  • Smith R, Oliver S, Ghahramani P, Kennedy S, Gilmore E, Duvauchelle T, Hammett T (2006) The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects. Proc Am Soc Clin Oncol abstr 3124

    Google Scholar 

  • Suzuki K, Morita T, Tokue A (2005) Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol 12:152–158

    Article  PubMed  CAS  Google Scholar 

  • Taghian AG, Suit HD (1999) Animal systems for translational research in radiation oncology. Acta Oncol 38:829–838

    Article  PubMed  CAS  Google Scholar 

  • Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K (2004) Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)-sensitive and resistant xenograft models. Cancer Sci 95:984–989

    Article  PubMed  CAS  Google Scholar 

  • Troiani T, Lockerbie O, Morrow M, Eckhardt SG (2005) Sequence-dependent sensitivity of human colon cancer cells to oxaliplatin and ZD6474, a selective inhibitor of the EGFR/VEGFR tyrosine kinases. Proc Am Assoc Cancer Res 46: abstr 2171

    Google Scholar 

  • Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F (2005) Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 11:1268–1276

    PubMed  CAS  Google Scholar 

  • Varghese HJ, MacKenzie LT, Groom AC, Ellis CG, Ryan A, MacDonald IC, Chambers AF (2003) The vascular-targeting agent, ZD6126, and the antiangiogenic agent, ZD6474, inhibit liver metastases via differential effects on metastatic vasculature. Clin Cancer Res 9:6141S

    Google Scholar 

  • Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090–5101

    PubMed  CAS  Google Scholar 

  • Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655

    PubMed  CAS  Google Scholar 

  • Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D

    Google Scholar 

  • Skinner M, Morse M, Burch W, Schlumberger M (2006) A Phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Proc Am Soc Clin Oncol abstr 5533

    Google Scholar 

  • Wilkinson RW, Ryan AJ, Wedge SR, Pyrah IT, Mandir N, Goodlad RA (2004) The VEGF receptor tyrosine kinase inhibitor ZD6474 significantly reduces intestinal tumor burden in the Min mouse. Proc Am Assoc Cancer Res 45:1075

    Google Scholar 

  • Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145–147

    Article  PubMed  CAS  Google Scholar 

  • Williams KJ, Telfer BA, Stratford IJ, Wedge SR (2003) Schedule-dependent effects of ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy in a lung tumor xenograft model. Clin Cancer Res 9:6141S

    Google Scholar 

  • Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10:8587–8593

    Article  PubMed  CAS  Google Scholar 

  • Wu W, Isobe T, Itasaka S, Shintani T, Langley RR, Onn A, Hansen JC, O’Reilly MS, Herbst RS (2004a) ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. Proc Am Assoc Cancer Res 45:1051

    Google Scholar 

  • Wu W, Onn A, Shintani T, O’Reilly MS, Herbst RS (2004b) ZD6474 enhances the anticancer efficacy of paclitaxel in human lung cancer models. Angiogenesis 7[Suppl 1]:25

    Google Scholar 

  • Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A, Sone S (2005) Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 11:8789–8798

    Article  PubMed  CAS  Google Scholar 

  • Zeng Y, Opeskin K, Baldwin ME, Horvath LG, Achen MG, Stacker SA, Sutherland RL, Williams ED (2004) Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin Cancer Res 10:5137–5144

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Astra Zeneca Pharmaceuticals, F433 Alderley House Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK

    Alan Barge & Anderson J. Ryan

Authors
  1. Alan Barge
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anderson J. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Tumorbiologie, Breisacher Str. 117, 79106, Freiburg i. Br., Germany

    Dieter Marmé PhD (Professor) (Professor)

  2. DKFZ, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    Norbert Fusenig MD (Professor, former Head of Division of Carcinogenesis and Differentiation) (Professor, former Head of Division of Carcinogenesis and Differentiation)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Barge, A., Ryan, A.J. (2008). Vandetanib (ZACTIMA™; ZD6474): Preclinical and Clinical Development. In: Marmé, D., Fusenig, N. (eds) Tumor Angiogenesis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-33177-3_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-33177-3_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-33176-6

  • Online ISBN: 978-3-540-33177-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation